PET/CT in endocarditis: Kouijzer and colleagues provide an overview of 18F-FDG PET/CT as the diagnostic imaging modality of choice in patients with infectious endocarditis, with an emphasis on detection and localization of septic foci.
Page 1045
Absorbed dose and PFS after RIT: Dewaraja and colleagues identify patient-specific dosimetric and nondosimetric factors predicting progression-free survival in non-Hodgkin lymphoma after 131I-tositumomab radioimmunotherapy.
Page 1047
NaF PET outside the prostate: Hillner and colleagues report on National Oncologic PET Registry data assessing the impact of 18F-sodium fluoride PET on intended management of Medicare patients with suspected or known osseous metastasis.
Page 1054
Surveillance PET/CT and survival: Antoniou and colleagues assess the added value of follow-up 18F-FDG PET/CT in clinical assessment and prediction of survival outcomes in patients with biopsy-proven lung cancer.
Page 1062
Optimal PET/CT imaging during RT for NSCLC: Everitt and colleagues use serial 18F-FDG and 18F-FLT PET/CT to observe cellular metabolism and proliferation as signs of early response in patients with non–small cell lung cancer during chemoradiation therapy.
Page 1069
18F-FLT PET in acute hematotoxicity: Leimgruber and colleagues investigate the potential of 18F-FLT PET to monitor acute effects of chemotherapy on cellular proliferation and its recovery in bone marrow, spleen, and liver during treatment with 2 different chemotherapy regimens.
Page 1075
PET and neoadjuvant erlotinib therapy: van Gool and colleagues evaluate the timing of metabolic response monitoring with 18F-FDG PET/CT early in erlotinib treatment in patients with early-stage non–small cell lung cancer.
Page 1081
89Zr-bevacizumab in NETs: van Asselt and colleagues explore the effect of everolimus on tumor uptake of the radiolabeled vascular endothelial growth factor A antibody bevacizumab using PET in patients with advanced neuroendocrine tumors.
Page 1087
PET/CT in infectious endocarditis: Kestler and colleagues study the clinical and practical impacts of systematic PET/CT imaging, from vertex to mid thigh, on diagnosis of infectious embolisms in patients with infectious endocarditis.
Page 1093
SPECT–MR and PET in pediatric epilepsy: Perissinotti and colleagues compare the results of video electroencephalography, brain MR, interictal SPECT, ictal SPECT, and subtraction ictal SPECT coregistered to MR imaging with those of interictal 18F-FDG PET in pediatric patients with epilepsy.
Page 1099
BBB P-gp activity in AD: Deo and colleagues elucidate relationships between reductions in regional cerebral blood flow and blood–brain barrier P-glycoprotein activity in patients with mild Alzheimer disease and cognitively normal participants.
Page 1106
PET and MR in MS: Colasanti and colleagues use 18F-PBR111 PET and MR imaging to measure relative binding in the lesional, perilesional, and surrounding normal-appearing white matter of patients with multiple sclerosis, as a potential index of innate immune response.
Page 1112
18F-FPEB radiation dosimetry: Kessler and colleagues report on human radiation dosimetry and associated recommendations with this potent and specific PET radioligand for the metabotropic glutamate receptor subtype 5.
Page 1119
Quantification of 18F-fluoride uptake: Raijmakers and colleagues assess the performance of various clinically useful simplified methods for 18F-fluoride PET measurement of bone metabolism and bone blood flow and compare these with full kinetic analysis.
Page 1122
Exocrine pancreas stress test: O and colleagues detail the development of a noninvasive imaging test of pancreatic exocrine function using 11C-acetate PET imaging before and after intravenous secretin stimulation.
Page 1128
PET drug regulatory requirements: Schwarz and colleagues provide an educational view of U.S. Food and Drug Administration oversight of PET drug production for clinical and clinical research uses, including a review of compliance, inspection, and reporting regulations.
Page 1132
PET and breast microcalcifications: Wilson and colleagues offer preliminary evidence that 18F-NaF PET imaging can detect breast cancer by targeting the hydroxyapatite lattice within the tumor microenvironment with high specificity and soft-tissue contrast-to-background ratio while differentiating tumors from inflammation.
Page 1138
Optimizing 11C-acetate tumor imaging: Lewis and colleagues measure uptake and metabolism of 11C-acetate on PET in mouse prostate and lung cancer models to investigate the time course of complete incorporation into tumor metabolites.
Page 1144
In vivo labeling of albumin: Niu and colleagues describe the development of an albumin labeling method to allow PET imaging of cardiac function after myocardial infarction and of vascular leakage and increased permeability in inflammatory diseases and malignant tumors.
Page 1150
Fibrin-targeting PET probes: Blasi and colleagues provide details on 4 new 64Cu- or Al18F-labeled PET probes based on fibrin-specific peptides and suitable for in vivo imaging of thrombus.
Page 1157
18F-labeled D2/D3 receptor agonist: Finnema and colleagues review their research in nonhuman primates with 18F-MCL-524 PET and discuss the tracer’s suitability for clinical quantification of D2/D3 receptor binding.
Page 1164
α2C-adrenoceptor PET tracer: Arponen and colleagues report on the development and preclinical evaluation of a PET tracer for α2C adrenoceptor imaging and highlight its potential in neuropsychiatric disorders.
Page 1171
18F-DEG-VS-NT synthesis: Wu and colleagues detail a simple and efficient method for 18F labeling of a thiolated neurotensin peptide for neurotensin receptor–targeted imaging.
Page 1178
κ-opioid antagonist tracer: Zheng and colleagues review their experience in developing the selective κ-opioid receptor 11C-LY2459989 as a PET radioligand and characterize its imaging performance in nonhuman primates.
Page 1185
18F-EF5 hypoxia imaging: Chitneni and colleagues look at tumor uptake of this radiolabeled PET tracer and binding of unlabeled tracer and the potential for combining them in assessment of hypoxia at both macroscopic and microregional levels.
Page 1192
Dedicated breast PET scanner: Miyake and colleagues evaluate the performance characteristics of a newly developed dedicated breast PET scanner, using National Electrical Manufacturers Association NU 4-2008 standards.
Page 1198
Engineered antibodies to improve PET: Swiercz and colleagues describe preclinical studies on a 124I/125I-labeled, antibody-based inhibitor of the FcRn receptor with potential for resolving challenges in antibody-based PET imaging associated with long half-lives.
Page 1204
Diversification in 99mTc supply chain: Cutler and Schwarz discuss current global issues in availability of 99mTc and highlight progress in new production facilities, novel methods for production of 99Mo, and innovative generator elution systems.
Page 1208
- © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.